These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Kjær MB; George J; Kazankov K; Grønbæk H Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486 [TBL] [Abstract][Full Text] [Related]
4. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549 [TBL] [Abstract][Full Text] [Related]
5. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. Kuchay MS; Misra A Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920 [No Abstract] [Full Text] [Related]
6. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH). Senussi NH; McCarthy DM Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272 [No Abstract] [Full Text] [Related]
7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
8. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. Wong VW; Lazarus JV J Hepatol; 2021 Dec; 75(6):1267-1270. PubMed ID: 34464658 [No Abstract] [Full Text] [Related]
9. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717 [TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M Gene; 2020 Jun; 742():144549. PubMed ID: 32184169 [TBL] [Abstract][Full Text] [Related]
14. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clanton J; Subichin M Surg Clin North Am; 2016 Aug; 96(4):703-15. PubMed ID: 27473796 [TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. Eshraghian A; Hamidian Jahromi A World J Gastroenterol; 2014 Jul; 20(25):8102-9. PubMed ID: 25009382 [TBL] [Abstract][Full Text] [Related]